刘鸿诗. 核医学放射性同位素应用辐射环境影响评价[J]. 原子能科学技术,2004,38(zl):188-191.Liu Hongshi.Radiation environmental impact assessment of the radioisotope’s application on nuclear medical science[J]. Atomic energy science and technology.2004, 38(zl): 188-191（in Chinese）.
[3]
田健. 康增寿. 131I治疗Graves'甲亢:有效半衰期测定新方法[J]. 中国医药科学,2012,2(23):57-58.Tian Jian, Kang Zengshou. Iodine-131 treatment of Graves'hyperthyroidism：New means of effective half-life measurement[J].China medicine and pharmacy, 2012, 2(23): 57-58（in Chinese）.
[4]
J. B. R Ravichandran, Amal Al Saadi. Estimation of effective half life of clearance of radioactive Iodine (131I) in patients treated for hyperthyroidism and carcinoma thyroid[J]. Indian J Nucl Med, 2010, 29(2): 49-52.
柳青,刘辉. 某核医学科内放射防护的探讨[J]. 科技信息,2013(19):479.Liu Qing, Liu Hui. The discussion of radiological protection in a nuclear medicine[J]. Science & technology information, 2013(19): 479（in Chinese）.
刘长安. 关于医疗照射指导水平[J]. 中国医疗器械信息，2009,15(5):81-84.Liu Changan.Guidance level for medical exposure[J].China Medical Device Information, 2009,15(5):81-84（in Chinese）.
[14]
Commission of 2007 Recommendations. ICRP publication 105-Radiological Protection in Medicine[R]. 2007, 37(6).
钱爱君,高林峰, 郑钧正,等. 上海市2008年临床核医学的医疗照射水平分析[J]. 环境与职业医学,2009,26(6):541-544.Qian Aijun, Gao Linfeng, Zhen Jun zheng, et al. Medical exposure levels from clinical nuclear medicine in 2008 in shanghai.[J] Environ Occup Med, Dec, 2009, 26(6): 541-544（in Chinese）.
[17]
范六一，赵恒谦. 临床核医学诊断治疗中患者受照剂量指导水平的思考[J]. 中国辐射卫生,2003,12(1):47-48.Fan Liuyi, Zhao Hengqian. Thinking of the dose guidance level of the patient in clinical nuclear medicine diagnosis and treatment [B]. Chin J Radiol Health, 2003, 12(1): 47-48（in Chinese）.
